$BGMS Income Statement | Understand Stock

$BGMS

$0.95 -$0.01 (0.79%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Clinical trial supply
Product Revenue Fire Safety
Total revenues
Cost of sales
Research and development
General and administrative
Total operating expenses
Operating loss
Other income (expense):
Foreign exchange losses
Interest income
Gain on deconsolidation of former subsidiary
Other income, net
Total other income, net
Loss before taxes
Income tax benefit / (provision)
Net loss
Dividend on convertible exchangeable preferred shares
Beneficial conversion feature of Series B preferred stock
Deemed dividend on warrant exchange
Net loss applicable to common shareholders
Redeemable common shareholders
Common Stock
Total net loss applicable to common shareholders

Basic and diluted earnings per common share:
Net loss per share - basic (common shareholders)
Redeemable common shareholders
Common Stock
Total net loss per share - basic (common shareholders)
Net loss per share - diluted (common shareholders)
Redeemable common shareholders
Common Stock
Total net loss per share - diluted (common shareholders)
Weighted average common shares outstanding - basic
Redeemable common shareholders
Common Stock
Total weighted average common shares outstanding - basic

Weighted average common shares outstanding - diluted
Redeemable common shareholders
Common Stock
Total weighted average common shares outstanding - diluted

Comments